RESPIRATORY TREATMENT INNOVATION
. . . . . .
Respira is developing next-generation cardiopulmonary disease-targeted inhalation products.
Our advanced particle engineering and formulation approaches in combination with our proprietary device technologies are designed to enhance drug delivery to the lung periphery.
We are pioneering respiratory therapies for patients with pulmonary arterial hypertension (PAH)
. . . . . .
Our therapies are intended to provide acute relief from the most common symptoms of breathlessness and fatigue.
Phase 2 clinical trials of our leading pipeline candidate are underway
. . . . . .
Respira’s lead drug-device product candidate, RT234-PAH, is a first-in-class inhaled therapy intended for “as-needed” use by patients (PRN).
Learn more about our Phase 2B clinical trial in PAH [here]
Leading the fight for breath
. . . . . .
Our industry-leading experience and expertise is focused on therapeutic technology that we believe may provide substantial new therapeutic benefits for patients everywhere.